References
- JURDAA -RomEr, M., CRAWFORD, K., CYR, T. and INABA, T., 1994, Terfenadine metabolism in human liver: in vitro inhibition by macrolide antibiotics and azole antifungals. Drug Metabolism and Disposition, 22, 849–857.
- KAH-HING, J. L., LEESON, G. A., BURMASTER, S. D., HOOK, R. H., KEITH, M. K. and CHENG, L. K., 1995, Metabolism of terfenadine associated with CYP3A4 activity in human hepatic microsomes. Drug Metabolism and Disposition, 23, 631–636.
- KOBINGER, W., 1985, Specific bradycardic agents, a new approach to therapy in angina pectoris. Progress in Pharmacology, 5/4, 89–100.
- LOWRY, O. H., ROSEBROUGH, N. J., FARR, A. C. and RANDALL, R. J., 1951, Protein measurement with the Folin phenol reagent. Journal of Biological Chemistry, 193, 265–275.
- MONAHAN, B. P., FERGUSON, CL., KILLEAVY, ES., LLOYD, B. K. and CANTILENA, L. R., 1990. Torsades de pointes occuring in association with terfenadine use. Journal of the American Medical Association, 264, 2788–2790.
- NAPOLITANO, C., PRIORI, S. G. and SCHWARTZ, P. J., 1994, Torsade de pointes: mechanisms and management. Drugs, 47, 51–65.
- OMURA, T. and SATO, R., 1964, The carbon monoxide-binding pigment of liver microsomes: evidence for its hemoprotein nature. Journal of Biological Chemistry, 239, 2370–2378.
- THORMANN, J., MITROVIC V., RIEDEL, H., NEUZNER, J., STRASSER, R., BEHAVAR, H. and SCHLEPPER, M., 1993, Tedisamil (KC8857) is a new specific bradycardic drug: Does it also influence myocardial contractility? Analysis by the conductance (volume) technique in coronary artery disease. American Heart Journal, 125, 1235–1246.
- WALLACE, A. A., STUPIENSKI III, R. F., BASKIN, E. P., APPLEBY, S. D., KOTHSTEIN, T., GEHRET, J. R., KING, S. W., REMY, D. C. and LYNCH, J. L., 1995, Cardiac electrophysiologic and antiarrhythmic actions of tedisamil. Journal of Pharmacology and Experimental Therapeutics, 273, 166–173.